Breaking Finance News

Endo International plc – Ordinary Shares (NASDAQ:ENDP) has been downgraded to Hold in a statement by ValuEngine earlier today.

Boasting a price of $12.95, Endo International plc – Ordinary Shares (NASDAQ:ENDP) traded -2.03% lower on the day. With the last stock price close up -26.00% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the date range. Endo International plc – Ordinary Shares has recorded a 50-day average of $8.52 and a two hundred day average of $10.43. Volume of trade was down over the average, with 3,101,745 shares of ENDP changing hands under the typical 6,192,980

ValuEngine has downgraded Endo International plc – Ordinary Shares (NASDAQ:ENDP) to Hold in a statement released on 06/02/2017.

On 5/17/2017, Vetr Inc. released a statement for Endo International plc – Ordinary Shares (NASDAQ:ENDP) bumped up the target price from $0.00 to $11.34 that suggested a downside of -0.09%.

Performance Chart

Endo International plc - Ordinary Shares (NASDAQ:ENDP)

With a total market value of $0, Endo International plc – Ordinary Shares has with a one year low of $7.40 and a one year high of $21.87 .

A total of 19 equity analysts have released a ratings update on ENDP. Three equity analysts rating the company a strong buy, five equity analysts rating the company a buy, thirteen equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $30.05.

Brief Synopsis About Endo International plc – Ordinary Shares (NASDAQ:ENDP)

Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain management, urology, central nervous system disorders, immunosuppression, oncology, womenÂ’s health, and cardiovascular disease markets. The companyÂ’s U.S. Branded Pharmaceuticals segment offers pain management products, such as Lidoderm, OPAN ER, Percocet, and Voltare Gel. This segment also provides Supprelin LA for central precocious puberty treatment; XIAFLEX for treating PeyronieÂ’s and DupuytrenÂ’s contracture diseases; Fortesta Gel for hypogonadism treatment; Testim Gel for the treatment of endogenous testosterone; Frova for migraine headaches; Valstar, a sterile solution for intravesical instillation of valrubicin; Vantas for the palliative treatment of advanced prostate cancer; Aveed for the treatment of low testosterone; TESTOPEL, a long-acting implantable pellet; and NASCOBAL, a nasal spray. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, including attention deficit hyperactivity disorder, pain, womenÂ’s health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, as well as for government healthcare programs. The company also provides injectables for the treatment of pain, anti-infectives, cardiovascular, and other therapeutics areas. It sells its branded pharmaceuticals and generics directly, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.